CN119212986A - 作为apol1的抑制剂的螺哌啶衍生物及其使用方法 - Google Patents
作为apol1的抑制剂的螺哌啶衍生物及其使用方法 Download PDFInfo
- Publication number
- CN119212986A CN119212986A CN202380030501.1A CN202380030501A CN119212986A CN 119212986 A CN119212986 A CN 119212986A CN 202380030501 A CN202380030501 A CN 202380030501A CN 119212986 A CN119212986 A CN 119212986A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- groups
- optionally substituted
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263307926P | 2022-02-08 | 2022-02-08 | |
| US63/307926 | 2022-02-08 | ||
| PCT/US2023/012583 WO2023154314A1 (en) | 2022-02-08 | 2023-02-08 | Spiro piperidine derivatives as inhibitors of apol1 and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119212986A true CN119212986A (zh) | 2024-12-27 |
Family
ID=85415293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380030501.1A Pending CN119212986A (zh) | 2022-02-08 | 2023-02-08 | 作为apol1的抑制剂的螺哌啶衍生物及其使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250195483A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4476207A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025505645A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119212986A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023218940A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251155A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024012060A2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023154314A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3897833T (lt) | 2018-12-17 | 2026-04-27 | Vertex Pharmaceuticals Incorporated | Apol1 inhibitoriai ir jų panaudojimo būdai |
| EP4097083A1 (en) | 2020-01-29 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| EP4146633A4 (en) | 2020-05-07 | 2024-09-25 | Rambam Med-Tech Ltd. | COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1 |
| JP2023530271A (ja) | 2020-06-12 | 2023-07-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Apol1の阻害剤及びこれを使用する方法 |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| BR112023003423A2 (pt) | 2020-08-26 | 2023-03-21 | Vertex Pharma | Inibidores de apol1 e métodos de uso destes |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8222288B2 (en) * | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| CN101563324A (zh) * | 2006-12-22 | 2009-10-21 | 弗·哈夫曼-拉罗切有限公司 | 螺-哌啶衍生物 |
| JP2017535545A (ja) * | 2014-11-21 | 2017-11-30 | ラボラトリオス・デル・デエレ・エステベ・エセ・ア | 疼痛に対する多様な活性を有するスピロ−イソキノリン−1,4’−ピペリジン化合物 |
| CN108884096B (zh) * | 2016-02-08 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 作为ddr1抑制剂的螺二氢吲哚酮 |
| US12698266B2 (en) * | 2019-12-19 | 2026-08-04 | Casma Therapeutics, Inc. | TRPML modulators |
| US20230014907A1 (en) * | 2020-06-12 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
-
2023
- 2023-02-08 WO PCT/US2023/012583 patent/WO2023154314A1/en not_active Ceased
- 2023-02-08 CN CN202380030501.1A patent/CN119212986A/zh active Pending
- 2023-02-08 US US18/836,681 patent/US20250195483A1/en active Pending
- 2023-02-08 AU AU2023218940A patent/AU2023218940A1/en active Pending
- 2023-02-08 EP EP23708332.4A patent/EP4476207A1/en active Pending
- 2023-02-08 CA CA3251155A patent/CA3251155A1/en active Pending
- 2023-02-08 JP JP2024546423A patent/JP2025505645A/ja active Pending
-
2024
- 2024-09-04 CO CONC2024/0012060A patent/CO2024012060A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023218940A1 (en) | 2024-08-22 |
| US20250195483A1 (en) | 2025-06-19 |
| CA3251155A1 (en) | 2023-08-17 |
| EP4476207A1 (en) | 2024-12-18 |
| CO2024012060A2 (es) | 2024-09-30 |
| WO2023154314A1 (en) | 2023-08-17 |
| JP2025505645A (ja) | 2025-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023154314A1 (en) | Spiro piperidine derivatives as inhibitors of apol1 and methods of using same | |
| JP6982054B2 (ja) | Glp−1受容体アゴニストおよびその使用 | |
| CA3255513A1 (en) | HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN | |
| US12421249B2 (en) | Inhibitors of APOL1 and methods of using same | |
| CN112566637A (zh) | Glp-1受体激动剂及其用途 | |
| JP2022547952A (ja) | Brd9二機能性分解誘導薬及びその使用方法 | |
| JP2021091683A (ja) | 2−((4−((S)−2−(5−クロロピリジン−2−イル)−2−メチルベンゾ[d][1,3]ジオキソール−4−イル)ピペリジン−1−イル)メチル)−1−(((S)−オキセタン−2−イル)メチル)−1H−ベンゾ[d]イミダゾール−6−カルボン酸の1,3−ジヒドロキシ−2−(ヒドロキシメチル)プロパン−2−アミン塩の固体形態 | |
| CN102325754B (zh) | 含杂原子的环状化合物 | |
| WO2022194269A1 (zh) | 新型egfr降解剂 | |
| CN115087440A (zh) | Trpml调节剂 | |
| WO2012176763A1 (ja) | 新規インダゾール誘導体 | |
| WO2023154309A1 (en) | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same | |
| US12612379B2 (en) | Inhibitors of APOL1 and methods of using same | |
| CN118632850A (zh) | Apol1的螺环抑制剂和其使用方法 | |
| WO2015079692A1 (ja) | ウレア誘導体、またはその薬理学的に許容される塩 | |
| WO2020103817A1 (zh) | TGF-βR1抑制剂及其应用 | |
| WO2020192652A1 (zh) | 酰胺类化合物制备方法及其在医药领域的应用 | |
| JP2025505647A (ja) | Apol1阻害剤としての2-メチル-4’,5’-ジヒドロピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、およびそれを使用する方法 | |
| WO2022223033A1 (zh) | Sos1降解剂及其制备方法和应用 | |
| CN114667145A (zh) | 与tdp-43结合的用于治疗肌萎缩性侧索硬化症和相关病症的分子 | |
| CA3177335A1 (en) | Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators | |
| WO2025109540A1 (en) | Macrocyclic compounds as kif18a inhibitors | |
| WO2024217481A1 (zh) | Egfr降解剂、其药物组合物及其用途 | |
| WO2019062657A1 (zh) | 氮杂环类衍生物、其制备方法及其医药用途 | |
| KR20260061216A (ko) | 에모파밀 결합 단백질 억제제로서의 피라졸릴 화합물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |